ANGIODYNAMICS INC
ANGONasdaq
$13.51
↓ -4.5%Jul 17 close · end-of-day
Price
1Y↑ +57.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$561.0M
Enterprise Value
$507.1M
P/E
—
P/S
1.8
P/B
3.3
EV/EBITDA
—
PEG
—
FCF Yield
0.1%
Dividend Yield
—
Revenue (TTM)
$320.2M
Net Income (TTM)
-$36.7M
Free Cash Flow (TTM)
$508,000.00
Gross Margin
54.6%
Operating Margin
-12.5%
Net Margin
-11.5%
ROE
-21.5%
ROIC
-27.0%
Debt / Equity
—
Net Cash
$53.9M
Return 1Y
+54.6%
Company profile
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems.
- CEO
- James C. Clemmer
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 760
- Headquarters
- New York
- Website
- angiodynamics.com
Management & directors
- Weiss Lawrence TSVP, Chief Legal Officer
- Trowbridge Stephen AEVP and CFO
- Clemmer James CPresident and CEO
- Campbell Chad ThomasSVP/GM, Vascular Access
- Nighan Warren JrSVP Quality and Regulatory
- Piccinini LauraSVP International
Roles derived from SEC Form 4 filings.
Earnings
ANGO Q4 2026 Earnings
Period ends 2026-05-31
MetricActualYoY
Revenue$86.6M↑ +8.0%
Diluted EPS-$0.28↑ +86.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $291.0M | $316.2M | $338.8M | $303.9M | $292.5M | $320.2M |
| Gross profit | $156.8M | $165.7M | $174.2M | $154.7M | $157.7M | $174.9M |
| Operating income | -$35.3M | -$28.5M | -$51.2M | -$192.4M | -$40.0M | -$39.9M |
| Net income | -$31.5M | -$26.5M | -$52.4M | -$184.3M | -$34.0M | -$36.7M |
| Diluted EPS | -$0.82 | -$0.68 | -$1.33 | -$4.59 | -$0.83 | -$0.88 |
| Operating cash flow | $24.1M | -$7.2M | $78,000.00 | -$28.2M | -$10.1M | $3.1M |
| Free cash flow | $18.9M | -$11.5M | -$3.7M | -$30.7M | -$14.6M | $508,000.00 |
| Gross margin | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% | 54.6% |
| Operating margin | -12.1% | -9.0% | -15.1% | -63.3% | -13.7% | -12.5% |
| Net margin | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% | -11.5% |
| Line item | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $72.8M | $72.0M | $80.2M | $75.7M | $79.4M | $78.4M | $86.6M |
| Gross profit | $36.7M | $39.9M | $38.9M | $42.2M | $41.9M | $44.8M | $41.5M | $46.8M |
| Operating income | -$13.1M | -$11.1M | -$10.0M | -$5.8M | -$10.7M | -$6.1M | -$13.0M | -$10.2M |
| Net income | -$12.8M | -$10.7M | -$4.4M | -$6.0M | -$10.9M | -$6.3M | -$8.1M | -$11.4M |
| Diluted EPS | -$0.31 | -$0.26 | -$0.11 | -$0.15 | -$0.26 | -$0.15 | -$0.19 | -$0.28 |
| Operating cash flow | -$18.3M | $2.5M | -$13.2M | $18.8M | -$15.9M | $4.7M | -$3.1M | $17.5M |
| Free cash flow | -$19.3M | $1.7M | -$15.0M | $18.0M | -$16.6M | $4.2M | -$4.1M | $17.0M |
| Gross margin | 54.4% | 54.8% | 54.0% | 52.7% | 55.3% | 56.4% | 52.9% | 54.0% |
| Operating margin | -19.4% | -15.2% | -13.9% | -7.2% | -14.1% | -7.7% | -16.5% | -11.8% |
| Net margin | -19.0% | -14.7% | -6.1% | -7.5% | -14.4% | -8.0% | -10.3% | -13.2% |
Company news
Jul 14, 2026
- 6d agoAngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challengesfinance.yahoo.com
- 6d agoAngioDynamics Q4 Earnings Call Highlightsmarketbeat.com
- 6d agoAngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimatesfinance.yahoo.com
- 6d agoAngioDynamics Tops Revenue Forecasts and Raises Sales Outlook for Fiscal 2027 (ANGO)investorshub.advfn.com
- 6d agoAngioDynamics: Fiscal Q4 Earnings Snapshotfinance.yahoo.com
- 6d agoAngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitabilityfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-21 | Weiss Lawrence T· SVP, Chief Legal Officer | Buy | 10,000 | $11.81 | $118,100.00 | filing |
| 2025-10-13 | Trowbridge Stephen A· EVP and CFO | Buy | 890 | $11.16 | $9,932.40 | filing |
| 2025-10-09 | Clemmer James C· President and CEO | Buy | 10,000 | $11.15 | $111,500.00 | filing |
| 2025-07-21 | Trowbridge Stephen A· EVP and CFO | Tax withholding | 667 | $8.99 | $5,996.33 | filing |
| 2025-07-21 | Campbell Chad Thomas· SVP/GM, Vascular Access | Tax withholding | 395 | $8.99 | $3,551.05 | filing |
| 2025-07-21 | Nighan Warren JR· SVP Quality and Regulatory | Tax withholding | 277 | $8.99 | $2,490.23 | filing |
| 2025-07-20 | Clemmer James C· President and CEO | Tax withholding | 3,673 | $8.99 | $33,020.27 | filing |
| 2025-07-20 | Clemmer James C· President and CEO | Tax withholding | 2,982 | $8.69 | $25,913.58 | filing |
| 2025-07-20 | Trowbridge Stephen A· EVP and CFO | Tax withholding | 717 | $8.69 | $6,230.73 | filing |
| 2025-07-20 | Piccinini Laura· SVP International | Tax withholding | 616 | $8.69 | $5,353.04 | filing |
| 2025-07-20 | Campbell Chad Thomas· SVP/GM, Vascular Access | Tax withholding | 359 | $8.69 | $3,119.71 | filing |
| 2025-07-20 | Nighan Warren JR· SVP Quality and Regulatory | Tax withholding | 251 | $8.69 | $2,181.19 | filing |
| 2025-07-19 | Clemmer James C· President and CEO | Tax withholding | 8,307 | $8.69 | $72,187.83 | filing |
| 2025-07-19 | Trowbridge Stephen A· EVP and CFO | Tax withholding | 2,585 | $8.69 | $22,463.65 | filing |
| 2025-07-19 | Piccinini Laura· SVP International | Tax withholding | 1,983 | $8.69 | $17,232.27 | filing |
| 2025-07-19 | Campbell Chad Thomas· SVP/GM, Vascular Access | Tax withholding | 1,025 | $8.69 | $8,907.25 | filing |
| 2025-07-19 | Nighan Warren JR· SVP Quality and Regulatory | Tax withholding | 735 | $8.69 | $6,387.15 | filing |
| 2025-07-19 | Clemmer James C· President and CEO | Tax withholding | 344 | $8.69 | $2,989.36 | filing |
| 2025-07-17 | Piccinini Laura· SVP International | Tax withholding | 3,074 | $8.74 | $26,866.76 | filing |
| 2025-07-16 | DONNELLY HOWARD W | Award | 17,675 | $0.00 | $0.00 | filing |
| 2025-07-16 | Burgess Lorinda | Award | 17,675 | $0.00 | $0.00 | filing |
| 2025-07-16 | Piccinini Laura· SVP International | Award | 32,423 | $0.00 | $0.00 | filing |
| 2025-07-16 | Auen Eileen O'Shea | Award | 17,675 | $0.00 | $0.00 | filing |
| 2025-07-16 | Tarnoff Michael E | Award | 17,675 | $0.00 | $0.00 | filing |
| 2025-07-16 | REED JAN STERN | Award | 17,675 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.